| Literature DB >> 33461939 |
Takeshi Hattori1, Atsushi Saito2, Hirofumi Chiba3, Koji Kuronuma2, Masaru Amishima4, Daisuke Morinaga4, Yasuo Shichinohe5, Yasuyuki Nasuhara6, Satoshi Konno7.
Abstract
BACKGROUND: Coronavirus disease (COVID-19) emerged in January 2020 in Sapporo city, and the outbreak has shown two peaks.Entities:
Keywords: COVID-19; Characteristics; Medical care facility; Outbreak waves; Sapporo
Year: 2021 PMID: 33461939 PMCID: PMC7775652 DOI: 10.1016/j.resinv.2020.11.008
Source DB: PubMed Journal: Respir Investig ISSN: 2212-5345
Characteristics of patients according to study periods.
| Total (n = 260) | Period 1 (n = 46) | Period 2 (n = 159) | Period 3 (n = 55) | p value | |
|---|---|---|---|---|---|
| Male, n (%) | 129 (49.6) | 23 (50.0) | 77 (48.4) | 29 (52.7) | 0.858 |
| Age, median (range) | 62 (11–99) | 59 (22–84) | 57 (11–99) | 72 (20–92) | 0.002 |
| 221 (85.0) | 39 (84.8) | 137 (86.2) | 45 (81.8) | 0.839 | |
| Severity | |||||
| Mild, n (%) | 170 (65.4) | 32 (69.6) | 106 (66.7) | 32 (59.2) | 0.4208 |
| Moderate, n (%) | 55 (21.2) | 5 (10.9) | 31 (19.5) | 19 (34.6) | 0.0106 |
| Severe, n (%) | 35 (13.5) | 9 (19.6) | 22 (13.8) | 4 (7.3) | 0.1922 |
| ECMO†, n (%) | 8 (3.1) | 4 (8.7) | 3 (1.9) | 1 (1.8) | 0.0564 |
| Health care provider, n (%) | 44 (16.9) | 0 (0) | 43 (27.0) | 1 (1.8) | <0.0001 |
| Inpatients/Medical care facility users, n (%) | 54 (20.8) | 1 (2.2) | 36 (22.6) | 17 (30.9) | 0.0012 |
| Others, n (%) | 162 (62.3) | 45 (97.8) | 80 (50.3) | 37 (67.3) | <0.0001 |
| 27 (10.4) | 1 (2.2) | 21 (13.2) | 5 (9.1) | 0.2401 | |
| Prognosis | |||||
| Back at home, n (%) | 112 (43.1) | 38 (82.6) | 48 (30.2) | 26 (47.3) | <0.0001 |
| Transferred to an accomodation facilities, n (%) | 65 (25.0) | 0 (0) | 65 (40.9) | 0 (0) | 0.1402 |
| Transferred to another hospital, n (%) | 60 (23.1) | 8 (17.4) | 34 (21.4) | 18 (32.7) | <0.0001 |
| Death, n (%) | 15 (5.8) | 0 (0) | 11 (6.9) | 4 (7.3) | 0.1799 |
| Still hospitalization | 8 (3.1) | 0 (0) | 1 (0.6) | 7 (12.7) | <0.0001 |
| Duration of hospitalization (day), rmedian (range) | 13 (1–107) | 15 (4–107) | 12.5 (1–75) | 10 (4–49) | 0.1555 |
| Duration from onset to admission (day), median (range) | 8 (1–28) | 8 (1–27) | 8 (1–28) | 6 (1–15) | 0.0003 |
| Medication (off-label use), n (%) | 162 (62.3) | 24 (52.2) | 99 (62.3) | 39 (70.9) | 0.1538 |
| Cyclesonidemm, n (%) | 128 (49.2) | 21 (45.7) | 75 (47.2) | 32 (58.2) | 0.3216 |
| Favipiravir, n (%) | 116 (44.6) | 11 (23.9) | 80 (50.3) | 25 (45.5) | 0.0065 |
| Ritonavir/Lopiravir, n (%) | 11 (4.2) | 9 (19.6) | 2 (1.3) | 0 (0) | <0.0001 |
| Camostat mesilate, n (%) | 4 (1.5) | 0 (0) | 4 (2.5) | 0 (0) | 0.2752 |
| Nafamostat mesilate, n (%) | 9 (3.5) | 0 (0) | 9 (5.7) | 0 (0) | 0.0581 |
| Tocilizumab, n (%) | 7 (2.7) | 0 (0) | 0 (0) | 7 (12.7) | <0.0001 |
| Remdesivir, n (%) | 2 (0.8) | 0 (0) | 0 (0) | 2 (3.6) | 0.0234 |
| Predonisolone, n (%) | 17 (6.5) | 2 (4.4) | 7 (4.4) | 8 (14.6) | 0.0258 |
ECMO: Extracorporeal membrane oxygenation.
Fig. 1(A) The transition of positive PCR tests reported by date in Sapporo city. (B) The transition of the number of the newly admitted patients in two hospitals.
Fig. 2(A) Age distribution in each period (B) Proportion of the jobs and situations in each period.
Characteristics of patients stratified by jobs and situations.
| Health Providers (n = 44) | Inpatients/Medical Care Facility Users (n = 54) | Others (n = 162) | p value | |
|---|---|---|---|---|
| Male, n (%) | 15 (34.1) | 23 (42.6) | 91 (56.2) | 0.009 |
| Age, median (range) | 48 (21–85) | 79 (34–99) | 60.5 (11–92) | <0.0001 |
| 35 (79.6) | 42 (77.8) | 144 (88.9) | 0.170 | |
| Severity | ||||
| Mild, n (%) | 37 (84.1) | 35 (64.8) | 98 (60.5) | 0.014 |
| Moderate, n (%) | 5 (11.4) | 16 (29.6) | 34 (21.0) | 0.088 |
| Severe, n (%) | 2 (4.6) | 3 (5.6) | 30 (18.5) | 0.009 |
| ECMO, n (%) | 0 (0) | 1 (2.0) | 7 (4.3) | 0.302 |
| 1 (2.3) | 26 (48.2) | 0 (0) | <0.0001 | |
| Prognosis | ||||
| Back in home, n (%) | 13 (29.6) | 13 (24.1) | 86 (53.1) | 0.0003 |
| Transferred accomodation facilities, n (%) | 29 (65.9) | 3 (5.6) | 33 (20.4) | <0.0001 |
| Transferred anoher hospital, n (%) | 2 (4.6) | 33 (61.1) | 25 (15.4) | <0.0001 |
| Death, n (%) | 0 (0) | 2 (3.7) | 13 (8.0) | 0.099 |
| Still hospitalization | 0 (0) | 3 (5.6) | 5 (3.1) | 0.125 |
| Duration of hospitalization (day), rmedian (range) | 8.5 (2–28) | 23 (5–63) | 11 (1–107) | <0.0001 |
| Duration from onset to admission (day), median (range) | 6 (1–14) | 7.5 (1–27) | 8 (1–28) | 0.095 |
| Medication (off-label use), n (%) | 29 (65.9) | 27 (50.0) | 106 (65.4) | 0.111 |
| Cyclesonidemm, n (%) | 21 (47.7) | 20 (37.0) | 87 (53.7) | 0.103 |
| Favipiravir, n (%) | 23 (52.3) | 19 (35.2) | 74 (45.7) | 0.216 |
| Ritonavir/Lopiravir, n (%) | 1 (2.3) | 0 (0) | 10 (6.2) | 0.116 |
| Camostat mesilate, n (%) | 2 (4.6) | 1 (1.9) | 1 (0.6) | 0.168 |
| Nafamostat mesilate, n (%) | 0 (0) | 1 (1.9) | 8 (4.9) | 0.217 |
| Tocilizumab, n (%) | 0 (0) | 0 (0) | 7 (4.3) | 0.114 |
| Remdesivir, n (%) | 0 (0) | 0 (0) | 2 (1.2) | 0.544 |
| Predonisolone, n (%) | 1 (2.3) | 4 (7.4) | 12 (7.4) | 0.455 |
ECMO: Extracorporeal membrane oxygenation.
Characteristics of patients according to disease severity.
| Mild (n = 170) | Moderate (n = 55) | Severe (n = 35) | p value | |
|---|---|---|---|---|
| Male, n (%) | 74 (43.5) | 32 (58.2) | 23 (65.7) | 0.021 |
| Age, median (range) | 54.5 (11–99) | 73 (30–96) | 63 (22–84) | <0.0001 |
| 135 (79.4) | 51 (92.7) | 35 (100) | 0.011 | |
| ECMO, n (%) | 0 (0) | 0 (0) | 8 (22.9) | <0.0001 |
| Health care provider, n (%) | 37 (21.8) | 5 (9.1) | 2 (5.7) | 0.015 |
| Inpatients/Medical care facility users, n (%) | 35 (20.6) | 16 (29.1) | 3 (8.6) | 0.645 |
| Others, n (%) | 98 (57.7) | 34 (61.8) | 30 (85.7) | 0.008 |
| 19 (11.2) | 7 (12.7) | 1 (2.9) | 0.173 | |
| Prognosis | ||||
| Back in home, n (%) | 78 (45.9) | 28 (50.9) | 6 (17.1) | 0.003 |
| Transferred accomodation facilities, n (%) | 63 (37.1) | 2 (3.6) | 0 (0) | <0.0001 |
| Transferred anoher hospital, n (%) | 27 (15.9) | 15 (27.3) | 18 (51.4) | <0.0001 |
| Death, n (%) | 0 (0) | 7 (12.7) | 8 (22.9) | <0.0001 |
| Still hospitalization | 2 (1.2) | 3 (5.5) | 3 (8.6) | 0.088 |
| Duration of hospitalization (day), rmedian (range) | 10 (1–62) | 17.5 (4–63) | 19 (2–107) | <0.0001 |
| Duration from onset to admission (day), median (range) | 8 (1–28) | 7 (1–27) | 9 (1–21) | 0.248 |
| Medication (off-label use), n (%) | 82 (48.2) | 46 (83.6) | 34 (97.1) | <0.0001 |
| Cyclesonidemm, n (%) | 61 (35.9) | 36 (65.5) | 31 (88.6) | <0.0001 |
| Favipiravir, n (%) | 46 (27.1) | 39 (70.9) | 31 (88.6) | <0.0001 |
| Ritonavir/Lopiravir, n (%) | 4 (2.4) | 2 (3.6) | 5 (14.3) | 0.006 |
| Camostat mesilate, n (%) | 1 (0.6) | 2 (3.6) | 1 (2.9) | 0.222 |
| Nafamostat mesilate, n (%) | 0 (0) | 0 (0) | 9 (3.5) | <0.0001 |
| Tocilizumab, n (%) | 1 (0.6) | 4 (7.3) | 2 (5.7) | 0.014 |
| Remdesivir, n (%) | 0 (0) | 0 (0) | 2 (5,7) | 0.002 |
| Predonisolone, n (%) | 0 (0) | 12 (21.8) | 5 (14.3) | <0.0001 |
ECMO: Extracorporeal membrane oxygenation.
Fig. 3(A) Proportion of the disease severity by age. (B) Fatality (percentage of deaths per subjects) by age.